Alessia Rognone

767 total citations
21 papers, 494 citations indexed

About

Alessia Rognone is a scholar working on Oncology, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alessia Rognone has authored 21 papers receiving a total of 494 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 8 papers in Epidemiology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alessia Rognone's work include Pancreatic and Hepatic Oncology Research (13 papers), Neuroendocrine Tumor Research Advances (7 papers) and Cancer Treatment and Pharmacology (4 papers). Alessia Rognone is often cited by papers focused on Pancreatic and Hepatic Oncology Research (13 papers), Neuroendocrine Tumor Research Advances (7 papers) and Cancer Treatment and Pharmacology (4 papers). Alessia Rognone collaborates with scholars based in Italy, Switzerland and Russia. Alessia Rognone's co-authors include Michele Reni, Stefano Cereda, Paolo Passoni, Gianpaolo Balzano, Clara Fugazza, Eugenio Villa, Elena Mazza, Alessandro Zerbi, Valerio Di Carlo and Roberto Nicoletti and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

Alessia Rognone

20 papers receiving 485 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alessia Rognone Italy	10	354	149	131	119	118	21	494
Niklas Gebauer Germany	14	390 1.1×	280 1.9×	89 0.7×	103 0.9×	70 0.6×	68	660
L. Shulman United States	9	245 0.7×	346 2.3×	87 0.7×	56 0.5×	120 1.0×	14	591
Benjamin M. Parsons United States	12	204 0.6×	252 1.7×	38 0.3×	35 0.3×	90 0.8×	36	440
K C Lakshmaiah India	11	315 0.9×	92 0.6×	73 0.6×	63 0.5×	186 1.6×	28	544
Swee‐Peng Yap Singapore	7	287 0.8×	98 0.7×	59 0.5×	80 0.7×	255 2.2×	9	532
S.A.M. van de Schans Netherlands	14	247 0.7×	209 1.4×	40 0.3×	74 0.6×	115 1.0×	26	462
Woo Kun Kim South Korea	13	376 1.1×	40 0.3×	107 0.8×	180 1.5×	242 2.1×	36	643
Magali Verheecke Belgium	12	495 1.4×	93 0.6×	67 0.5×	204 1.7×	83 0.7×	24	792
N. Zielonke Netherlands	11	294 0.8×	103 0.7×	93 0.7×	96 0.8×	197 1.7×	20	557
Pamela J. Schlembach United States	13	179 0.5×	221 1.5×	127 1.0×	16 0.1×	198 1.7×	31	562

Countries citing papers authored by Alessia Rognone

Since Specialization

Citations

This map shows the geographic impact of Alessia Rognone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessia Rognone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessia Rognone more than expected).

Fields of papers citing papers by Alessia Rognone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alessia Rognone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessia Rognone. The network helps show where Alessia Rognone may publish in the future.

Co-authorship network of co-authors of Alessia Rognone

This figure shows the co-authorship network connecting the top 25 collaborators of Alessia Rognone. A scholar is included among the top collaborators of Alessia Rognone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessia Rognone. Alessia Rognone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Naldini, Matteo Maria, Giulia Viale, Alessia Rognone, et al.. (2024). Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice. Frontiers in Oncology. 14. 1374547–1374547. 4 indexed citations

Licata, Luca, Giulia Viale, Stefania Zambelli, et al.. (2023). 2090P Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice. Annals of Oncology. 34. S1098–S1098.

Paolino, Giovanni, Riccardo Pampena, Matteo Riccardo Di Nicola, et al.. (2022). Dermatological and Dermoscopic Baselines in BRCA Mutation Carriers. Frontiers in Medicine. 9. 863468–863468. 1 indexed citations

Mattei, Valentina Elisabetta Di, Paola Zucchi, Maria Grazia Patricelli, et al.. (2015). Consulenza genetica oncologica e qualità di vita: il ruolo delle strategie di coping e della sintomatologia psicopatologica nella fase pre-testale. Recenti Progressi in Medicina. 106(8). 380–4. 2 indexed citations

Cereda, Stefano, Carmen Belli, Alessia Rognone, Elena Mazza, & Michele Reni. (2013). Second-line therapy in advanced biliary tract cancer: What should be the standard?. Critical Reviews in Oncology/Hematology. 88(2). 368–374. 16 indexed citations

Reni, Michele, Gianpaolo Balzano, Giuseppe Aprile, et al.. (2012). Adjuvant PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) or Gemcitabine Followed by Chemoradiation in Pancreatic Cancer: A Randomized Phase II Trial. Annals of Surgical Oncology. 19(7). 2256–2263. 30 indexed citations

Cereda, Stefano, Michele Reni, Alessia Rognone, et al.. (2011). Salvage Therapy with Mitomycin and Ifosfamide in Patients with Gemcitabine-Resistant Metastatic Pancreatic Cancer: A Phase II Trial. Chemotherapy. 57(2). 156–161. 13 indexed citations

Reni, Michele, Stefano Cereda, Alessia Rognone, et al.. (2011). A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). Cancer Chemotherapy and Pharmacology. 69(1). 115–123. 52 indexed citations

Dell’Oca, I., C. Fiorino, Andrei Fodor, et al.. (2011). 868 poster SIMULTANEOUS INTEGRATED BOOST 18FDG-PET BASED HELICAL TOMOTHERAPY IN RADICAL LOCALLY ADVANCED HEAD AND NECK CANCER.. Radiotherapy and Oncology. 99. S335–S335. 1 indexed citations

10.

Reni, Michele, Lara Maria Pasetto, Alessandro Passardi, et al.. (2010). Treatment trends in metastatic pancreatic cancer patients: Is it time to change?. Digestive and Liver Disease. 43(3). 225–230. 6 indexed citations

11.

Reni, Michele, Nora Sartori, Andrea Mambrini, et al.. (2010). An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?. Anti-Cancer Drugs. 21(4). 459–464. 5 indexed citations

12.

Cereda, Stefano, Michele Reni, Alessia Rognone, et al.. (2010). XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.. PubMed. 30(11). 4785–90. 14 indexed citations

13.

Cereda, Stefano, Alessia Rognone, Elena Mazza, et al.. (2009). Weekly Epirubicin as Salvage Therapy in Patients with Gemcitabine-Resistant Advanced Pancreatic Cancers. Journal of Chemotherapy. 21(6). 698–700. 2 indexed citations

14.

Reni, Michele, Stefano Cereda, Gianpaolo Balzano, et al.. (2009). Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer. 115(12). 2630–2639. 98 indexed citations

15.

Reni, Michele, Stefano Cereda, Gianpaolo Balzano, et al.. (2009). Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology. 64(6). 1253–1259. 30 indexed citations

16.

Cereda, Stefano, Alessia Rognone, Michele Ghidini, et al.. (2009). A randomized phase II trial of two different four-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel. Journal of Clinical Oncology. 27(15_suppl). 4614–4614. 2 indexed citations

17.

Reni, Michele, Stefano Cereda, Giuseppe Aprile, et al.. (2009). 6599 Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine in pancreatic cancer: a randomized phase II trial. European Journal of Cancer Supplements. 7(2). 390–390. 1 indexed citations

18.

Ferrari, Andrea, Alessia Rognone, Michela Casanova, et al.. (2007). Colorectal carcinoma in children and adolescents: The experience of the Istituto Nazionale Tumori of Milan, Italy. Pediatric Blood & Cancer. 50(3). 588–593. 67 indexed citations

19.

Reni, Michele, Stefano Cereda, Paolo Passoni, et al.. (2007). A randomized phase II trial of PEXG (cisplatin, epirubicin, capecitabine, gemcitabine) or PDXG (docetaxel) regimen in advanced pancreatic adenocarcinoma. Journal of Clinical Oncology. 25(18_suppl). 4628–4628. 9 indexed citations

20.

Ferreri, Andrés J.M., Mario Regazzi, Felice Pasini, et al.. (2004). Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. British Journal of Cancer. 90(2). 353–358. 113 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact